GIST (Gastrointestinal Stromal Tumor): Causes, Risk Factors & Symptoms
What Is a GIST?
Gastrointestinal stromal tumors (GISTs) are rare cancers arising from the interstitial cells of Cajal (pacemaker cells of the GI tract) in the digestive system wall. Most occur in the stomach (60%) or small intestine (30%), but they can arise anywhere from the esophagus to the rectum.
Risk Factors
- Age: Median diagnosis at 60–65 years; rare under 40.
- Sex: Slightly more common in men.
- Genetic Mutations: ~80% have KIT mutations; ~10% have PDGFRA mutations. Most are sporadic, but familial syndromes exist.
- Neurofibromatosis Type 1 (NF1): Associated with multiple small intestinal GISTs.
- Carney Triad/Stratakis Syndrome: Rare syndromes including GIST, paraganglioma, and pulmonary chondroma.
Symptoms
Symptoms depend on tumor size and location. Many small GISTs are asymptomatic. Larger tumors may cause:
- Abdominal pain or discomfort
- Gastrointestinal bleeding (melena, hematemesis, anemia)
- Early satiety, nausea, vomiting
- Palpable abdominal mass
- Bowel obstruction or perforation (emergency)
Diagnosis
- Imaging: CT with contrast (preferred), MRI, or PET-CT for staging.
- Endoscopy/EUS: For mucosal lesions; allows biopsy.
- Biopsy: Core needle or endoscopic; confirms diagnosis and allows molecular testing (KIT/PDGFRA mutations).
- Pathology: Immunohistochemistry for CD117 (c-KIT), DOG1.
Treatment
- Surgery: Primary treatment for localized, resectable GIST. Goal is R0 resection with intact pseudocapsule; lymphadenectomy not routine.
- Adjuvant Imatinib: 3 years for high-risk resected GIST (tumor size >5 cm, high mitotic rate, rupture).
- Neoadjuvant Imatinib: For borderline resectable or large tumors to shrink before surgery.
- Advanced/Metastatic Disease: Imatinib first-line; sunitinib second-line; regorafenib third-line; ripretinib fourth-line. Avapritinib for PDGFRA exon 18 mutations.
- Radiation/Chemotherapy: Generally ineffective; radiation for palliation only.
Prognosis
5-year survival for localized GIST after surgery is ~90%. For metastatic disease, median survival with imatinib is ~5 years. Prognosis depends on risk stratification (NIH/AFIP or modified criteria: size, mitotic rate, site, rupture).
Prevention and Screening
No proven prevention. Patients with NF1 or family history should discuss surveillance (CT or endoscopic) with a specialist.
Infertility - Related Articles
- Ovulation Timing: How to Pinpoint Your Fertile Window
- Blocked Fallopian Tubes: Causes, Treatments & Fertility Options
- Male Reproductive System: Key Organs and Functions
- Ovulation Timing: Understanding Your Cycle and Fertile Window
- Proof of Delivery (POD): Methods, Importance, and Legal Role in Shipping
- Early Twin Detection: Ultrasound Timing and Identical vs. Fraternal Differences
- Y Chromosome & Male Infertility: Causes & Research
